Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Labeling for nicotine replacement products should direct physician consult, expert suggests.

This article was originally published in The Tan Sheet

Executive Summary

SMOKING CESSATION PRODUCT LABEL PHYSICIAN CONSULTATION DIRECTION necessary if the product is "not doing what it is supposed to do" as part of materials available to consumers, David Sachs, MD, Palo Alto Center for Pulmonary Disease Prevention, suggested at a June 9 meeting of FDA's Drug Abuse Advisory Committee in Bethesda, Md. Sachs addressed the committee during the open public hearing, saying nicotine replacement product labeling for consumers "must clearly...state, as is done for each and every other OTC category...when patients should see a physician because the medication is not doing what it is supposed to do."
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087181

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel